🔍

Vivanza Biosciences Ltd (530057)

📊 BSE: 530057 🏢 Pharmaceuticals 📢 Latest filing: 08 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Vivanza Biosciences' revenue was ₹9.3 Cr (+3.9% year on year, +46.1% on the previous quarter), and net profit ₹0.1 Cr (+66.7% year on year); the operating margin was -0.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹9.3	+3.9%	+46.1%
Operating profit	₹-0.1	to loss	loss narrowed
Net profit	₹0.1	+66.7%	from loss
EPS (₹)	0.04	+100.0%	from loss
Operating margin	-0.8%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Vivanza Biosciences Confirms Non-Applicability of Deviation Statement Under Regulation 32

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Oct 2026, 11:30 AM

Vivanza Biosciences Limited has submitted a regulatory update under Regulation 32 of SEBI LODR Regulations, 2015 for the period ending October 8, 2026. The company confirmed that it has not raised any funds via public issue, rights issue, or preferential issue. Consequently, the requirement to submit a statement of deviation or variation is not applicable.

Filing dated 08th October, 2026 under Regulation 32 of SEBI LODR Regulations, 2015
Reference to SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December, 2019
Company confirmed zero funds were raised via Public, Rights, or Preferential issues

💡 Track the upcoming quarterly financial results and business operations as this filing is purely administrative.

Vivanza Biosciences Releases FY26 Annual Report; 44th AGM Scheduled for Sep 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Aug 2026, 11:58 AM

Vivanza Biosciences Limited has published its Annual Report for FY 2025-26 and scheduled its 44th Annual General Meeting for September 11, 2026. Key agenda items include adoption of audited financial statements and approval of material related-party transactions up to Rs 100 Crore for FY 2026-27. The auditor's report highlights observations regarding interest-free loans (noted as a violation of Section 186(7)) and reliance on director certificates for expenses lacking supporting vouchers.

44th Annual General Meeting scheduled for Friday, September 11, 2026, via Video Conference.
Shareholder approval sought for material related-party transactions up to Rs 100 Crore in FY 2026-27.
Reported FY26 Revenue from Operations stood at Rs 11,591.06 lakhs compared to Rs 742.33 lakhs in FY25.
Auditor noted potential violation of Section 186(7) of the Companies Act, 2013 regarding interest-free loans granted by the company.

💡 Track the outcome of shareholder voting at the AGM on September 11, 2026, particularly regarding the Rs 100 Crore related-party transaction limit and corporate governance disclosures.

Vivanza Biosciences Convenes 44th AGM on Sept 11, 2026; Seeks ₹100 Cr RPT Approval

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Aug 2026, 11:45 AM

Vivanza Biosciences has released the Notice and Annual Report for its 44th Annual General Meeting scheduled for September 11, 2026. Key agenda items include the adoption of FY26 financial statements, reappointment of Managing Director Jayendra Mehta, and regularization of Additional Director H.A. Parikh. Additionally, shareholder approval is being sought for material related-party transactions of up to ₹100 crore for FY 2026-27, which is significant relative to its ₹116 crore TTM revenue.

44th AGM scheduled for Friday, September 11, 2026 at 03:30 PM via VC/OAVM
Approval sought for material related party transactions up to ₹100 Crore for FY 2026-27
Regularization of Mr. H.A. Parikh (appointed w.e.f. June 18, 2026) as Non-Executive Non-Independent Director
Auditor notes highlight interest-free loans given and lack of supporting expense vouchers covered by director certificates

💡 Track voting outcomes of the AGM resolutions on September 11, 2026, especially the ₹100 crore related-party transaction limit and corporate governance disclosures.

Vivanza Biosciences Approves 44th AGM, Borrowing Limit Hike & Related Party Proposals

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 17 Aug 2026, 04:06 PM

Vivanza Biosciences' Board has approved convening the 44th Annual General Meeting (AGM) and fixed September 04, 2026, as the cut-off date for member voting eligibility. Key agenda items submitted for shareholder approval include increasing borrowing limits under Section 180(1)(c) beyond paid-up capital and reserves, and sanctioning material Related Party Transactions for FY 2026-27. The Board also sought approval for loans, investments, and guarantees under Sections 185 and 186, along with adopting new MoA and AoA aligned with the Companies Act, 2013.

Approved convening of the 44th Annual General Meeting for FY 2025-26.
Fixed Friday, September 04, 2026, as the cut-off date to determine e-voting eligibility.
Proposing shareholder approval to increase borrowing limits under Section 180(1)(c).
Seeking approval for material Related Party Transactions during FY 2026-27 and transactions under Sections 185/186.

💡 Review the full AGM Notice and explanatory statement once published to evaluate specific financial limits for the proposed borrowing hikes and related party transaction disclosures.

Vivanza Biosciences to Seek Approval for Borrowings and Inter-Corporate Loans at 44th AGM

🔵 WATCH ⭐ 4/10

BOARD_MEETING 📅 12 Aug 2026, 06:08 PM

Vivanza Biosciences has scheduled a board meeting on August 17, 2026, to finalize details for its 44th Annual General Meeting (AGM). The board will consider seeking shareholder approval for increased borrowing limits (Section 180) and authorizations for loans, guarantees, and investments (Sections 185 and 186). This is critical as the company currently operates with a high Debt-to-Equity ratio of 2.50 and a small net worth of Rs 4 Cr. The cut-off date for e-voting eligibility has been set for September 4, 2026.

Board meeting scheduled for August 17, 2026, to approve the 44th AGM notice and Director's Report.
Seeking shareholder approval for borrowings under Section 180(1)(c) and loans/investments under Sections 185 and 186.
Cut-off date for determining member eligibility for e-voting is September 4, 2026.
Proposal to adopt new Memorandum and Articles of Association in line with the Companies Act, 2013.
Company currently carries Rs 10 Cr in debt against a small market cap of Rs 8 Cr.

💡 Investors should review the upcoming AGM notice to identify the specific monetary limits requested for new borrowings and inter-corporate loans, especially given the low promoter holding of 20%.

Vivanza Biosciences Reports Nil Fundraise via Public or Rights Issues

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Aug 2026, 11:56 AM

Vivanza Biosciences has filed a statement of non-applicability regarding Regulation 32 of SEBI (LODR) Regulations. The company confirmed it has not raised any funds through public issues, rights issues, or preferential issues during the reporting period. Consequently, there are no deviations or variations in fund utilization to report. This is a standard procedural filing for a micro-cap company with a market capitalization of approximately ‡8 Cr.

Confirmed zero funds raised through Public, Rights, or Preferential issues
Compliance filing under Regulation 32 of SEBI (LODR) Regulations, 2015
Statement dated August 8, 2026, confirms no deviation in fund usage
Company maintains a high Debt-to-Equity ratio of 2.50 as per latest financials

💡 Investors should focus on the company's operational performance and high debt levels (‡10 Cr) rather than this routine administrative filing.

Vivanza Biosciences Approves Q1 FY27 Results; TTM Revenue at Rs 116 Cr

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 07 Aug 2026, 01:29 PM

Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company operates with a very small market capitalization of Rs 8 Cr and has shown significant revenue volatility, with the previous quarter (Mar 2026) seeing a sharp drop to Rs 6.36 Cr from Rs 45.25 Cr in Dec 2025. The board also confirmed director qualifications and independence as per statutory requirements. Investors should note the high debt-to-equity ratio of 2.50 and low promoter holding of 20.02%.

Board approved unaudited financial results for the quarter ended June 30, 2026
The board meeting was brief, lasting 15 minutes from 12:45 PM to 1:00 PM
Company maintains a high debt-to-equity ratio of 2.50 based on latest financial context
TTM revenue stands at Rs 116 Cr, which is significantly higher than its Rs 8 Cr market cap
Promoter holding remains stagnant at 20.02% as of the latest reporting period

💡 Investors should examine the detailed P&L statement (Annexure A) to see if revenue has recovered from the low of Rs 6.36 Cr reported in the March 2026 quarter.

Vivanza Biosciences Approves Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 07 Aug 2026, 01:28 PM

Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a board meeting held on August 7, 2026. The company operates with a very small market cap of ‑8 Cr and a high debt-to-equity ratio of 2.50, making quarterly performance critical for solvency. While TTM revenue is significant at ‑116 Cr, the company has struggled with razor-thin operating margins of 0.6% and reported a loss of ‑0.45 Cr in the preceding March 2026 quarter. Investors should focus on whether the company has stabilized its bottom line in this new reporting period.

Board approved unaudited financial results for the quarter ended June 30, 2026
Company maintains a high Debt-to-Equity ratio of 2.50 as per latest financial context
TTM revenue stands at ‑116 Cr, which is 14.5x its current market capitalization of ‑8 Cr
Promoter holding remains relatively low at 20.02%
The meeting concluded within 15 minutes, starting at 12:45 P.M. and ending at 13:00 P.M.

💡 Review the detailed P&L in the full results filing to check for any improvement in the 0.6% operating margin and to see if the company has recovered from the ‑0.45 Cr loss reported in the previous quarter.

Vivanza Biosciences Approves Q1 FY27 Unaudited Financial Results

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 07 Aug 2026, 01:11 PM

Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a board meeting held on August 7, 2026. The company operates with a significant TTM revenue of ₹116 Cr relative to its small market capitalization of ₹8 Cr, but faces challenges with a thin operating margin of 0.6%. Investors should note the high debt-to-equity ratio of 2.50 and a relatively low promoter holding of 20.02%. The meeting was brief, concluding within 15 minutes.

Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Board meeting duration was 15 minutes, starting at 12:45 P.M. and concluding at 13:00 P.M.
Company maintains a high Debt-to-Equity ratio of 2.50 as per latest financial context
TTM Revenue of ₹116 Cr is significantly higher than the current Market Cap of ₹8 Cr
Promoter holding remains stagnant at 20.02% as of the last reporting period

💡 Investors should examine the detailed quarterly P&L to see if the company has recovered from the ₹0.45 Cr net loss reported in the March 2026 quarter and if operating margins have improved from the current 0.6%.

Board Meeting Rescheduled to August 7, 2026 for Q1 Results Approval

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 31 Jul 2026, 03:19 PM

Vivanza Biosciences has rescheduled its board meeting from August 1, 2026, to August 7, 2026. The primary agenda is to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This follows a volatile financial year where revenue surged to Rs 116 Cr in FY26 from Rs 7 Cr in FY25, though the company remains barely profitable with a TTM PAT of Rs 0 Cr. Investors should note the company's high debt-to-equity ratio of 2.50 and its micro-cap status with a market capitalization of only Rs 8 Cr.

Board meeting rescheduled from August 1, 2026, to August 7, 2026
Meeting to approve financial results for the quarter ended June 30, 2026
Company reported a net loss of Rs 0.45 Cr in the most recent quarter (March 2026)
Debt-to-equity ratio stands high at 2.50 with total debt of Rs 10 Cr
Promoter holding remains stagnant at 20.02% as of March 2026

💡 Investors should monitor the upcoming results on August 7, 2026, to evaluate if the company can improve its operating margins, which were thin at 0.6% on a TTM basis.

Aug 01 Board Meeting to Consider Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 28 Jul 2026, 05:52 PM

Vivanza Biosciences has scheduled a board meeting on August 01, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is coming off a volatile fiscal year where quarterly revenue dropped from Rs 55.36 Cr in Sep 2025 to just Rs 6.36 Cr in Mar 2026. With a thin operating margin of 0.6% and a high debt-to-equity ratio of 2.50, the upcoming results are critical for assessing liquidity and operational stability. The market cap remains small at Rs 7 Cr, making the stock highly sensitive to earnings surprises.

Board meeting scheduled for August 01, 2026, to approve Q1 FY27 results
Company reported a net loss of Rs 0.45 Cr in the most recent quarter (Mar 2026)
Operating margins are currently thin at 0.6% on a TTM basis
Debt of Rs 10 Cr significantly exceeds the Net Worth of Rs 4 Cr
Promoter holding has remained stagnant at 20.02% over the last four quarters

💡 Monitor the results on August 01 for any recovery in revenue and margins, and check for updates on debt servicing capabilities given the 2.50 D/E ratio.

Vivanza Biosciences Receives Unmodified Audit Opinion for FY Ended March 31, 2026

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 14 Jul 2026, 10:33 AM

Vivanza Biosciences has filed a formal declaration stating that its statutory auditors, M/s Shivam Soni & Co, have issued an audit report with an unmodified opinion for the financial year ended March 31, 2026. This filing is a mandatory compliance under SEBI Regulation 33(3)(d), confirming that the auditor found no material discrepancies in the company's financial statements. While this confirms the integrity of the accounting process, it does not provide specific financial performance metrics such as revenue or profit growth. The stock has seen negative returns of 16.2% over the last 12 months.

Statutory Auditor M/s Shivam Soni & Co issued an unmodified opinion for FY 2025-26
Declaration made pursuant to SEBI Regulation 33(3)(d)
Audit covers both the quarter and the full year ended March 31, 2026
Document dated July 11, 2026, following the close of the fiscal year

💡 Investors should review the full audited financial statements for FY26 to evaluate the company's fundamental performance, as this filing only confirms the audit's clean status.

View All 530057 Announcements on Live Market Tracking →